During this webinar, Dr. Yvan Caspar will describe in detail two complementary studies performed at the Centre Hospitalier Universitaire Grenoble Alpes (CHUGA) using the trio of ePlex® Blood Culture Identification Panels from GenMark Diagnostics for detection of bloodstream infections caused by Gram-negative, Gram-positive, and fungal pathogens. First, he will discuss the results of a retrospective study that assessed the analytical performance of the ePlex BCID Panels and the clinical outcomes based on these results.
For each positive blood culture included in the study, the patient’s health record was retrospectively reviewed by a clinical team to assess how the rapid detection of pathogens and antimicrobial resistance genes from positive blood cultures, using the ePlex BCID Panels, would have potentially changed the management of patients with bloodstream infections.
Dr. Caspar will then highlight initial data that has been collected and analyzed from the HEMOFAST prospective randomized clinical trial, which is a clinical and medico-economic evaluation of the ePlex BCID Panels for the diagnosis of bacteremia and fungemia compared to conventional microbiology. While the trial is still in progress, preliminary data will be presented to provide a glimpse into the benefits of the ePlex BCID Panels.
As the body of scientific literature for faster identification and management of bloodstream infections grows, the data generated at CHUGA continues to expand the evidence supporting the clinical utility of these technologies. The two studies being showcased in this webinar will provide a big-picture view of how the ePlex BCID Panels are improving rapid blood culture diagnostics.
Yvan Caspar is a clinical microbiologist at the bacteriology laboratory of Grenoble Alpes University Hospital (2,100 beds), which also hosts the French National Reference Center for Francisella. His main research focuses on Francisella and tularemia, antibiotic resistance and on the development of new therapeutic strategies. He is also interested in innovative rapid diagnosis technologies, in particular, techniques to improve the management of sepsis and antibiotic stewardship.